<DOC>
	<DOCNO>NCT01719432</DOCNO>
	<brief_summary>Studies show different percentage body fat alter way drug distribute body . This study use blood sample take different time point patient take Neupogen determine high body weight affect drug exposure . The information gather study help understand patient high body weight need different dosing plan . Patients study blood draw take Neupogen 6 time take Neuopen ( total 24 hour ) . These patient hospital already need make additional trip back blood drawn . A total 5-6 tablespoon blood drawn study . 15 obese patient 15 match , non-obese patient enrol study .</brief_summary>
	<brief_title>Effect Body Mass Filgrastim Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age great equal 18 year Receiving filgrastim 5mcg/kg Â± 10 % Admitted inpatient expect stay least 24 hour Weight &gt; 190 % ideal body weight ( IBW ) `` obese '' patient within 80 124 % IBW match control patient . Patient legally authorize representative understands voluntarily sign write informed consent prior studyspecific procedure . A copy sign informed consent form retain treating institution . Patients receive filgrastim within 24 hour prior enrollment Patients receive pegfilgrastim within 14 day prior enrollment Hypersensitivity reaction filgrastim related product Patients take lithium within 7 day enrollment Serum Creatinine &gt; 1.5 mg/dL Patients pregnant breastfeed Patients unable understand and/or render inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Filgrastim</keyword>
	<keyword>Obese</keyword>
	<keyword>Non-obese</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>